Somatostatin receptor subtypes mRNA in TSH-secreting pituitary adenomas: A case showing a dramatic reduction in tumor size during short octreotide treatment

Endocrine Journal

Volumn 54, Issue 3, 2007, Pages 371-378

  Horiguchi, Kazuhiko ^a   Yamada, Masanobu ^a   Umezawa, Ryohei ^a   Satoh, Teturo ^a   Hashimoto, Koshi ^a   Tosaka, Masahiko ^a   Yamada, Shozo ^b   Mori, Masatomo ^a  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TORANOMON HOSPITAL   (Japan)

Author keywords

Octreotide; Sstr; Tsh secreting adenoma

Indexed keywords

MESSENGER RNA; OCTREOTIDE; SOMATOSTATIN RECEPTOR;

ADULT; ARTICLE; CASE REPORT; HUMAN; MALE; PROTEIN EXPRESSION; THYROTROPIN SECRETING ADENOMA; TUMOR REGRESSION; TUMOR VOLUME;

ADENOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; OCTREOTIDE; PITUITARY NEOPLASMS; PROTEIN ISOFORMS; RECEPTORS, SOMATOSTATIN; RNA, MESSENGER; THYROTROPHS; TIME FACTORS; TUMOR BURDEN;

EID: 34547130844     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.K06-177     Document Type: Article

References (32)

1. Beck-Peccoz P, Brucker-Davis F, Persani L, Smallridge RC, Weintraub BD (1996) Thyrotropin-secreting pituitary tumors. Endocr Rev 17: 610-638.
2. Beck-Peccoz P, Persani L (2005) The Thyroid: Thyrotropin-induced thyrotoxicosis. In: Braverman LE and Utiger RD (eds) 9th ed. Lippincott Williams & Wilkins, Philadelphia; 500-507.
3. Dong Q, Brucker-Davis F, Weintraub BD, Smallridge RC, Carr FE, Battey J, Spiegel AM, Shenker A (1996) Screening of candidate oncogenes in human thyrotroph tumors: absence of activating mutations of the G alpha q, G alpha 11, G alpha s, or thyrotropin-releasing hormone receptor genes. J Clin Endocrinol Metab 81: 1134-1140.
4. Lamberts SW, Krenning EP, Reubi JC (1991) The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev 12: 450-482.
5. Comi RJ, Gesundheit N, Murray L, Gorden P, Weintraub BD (1987) Response of thyrotropin-secreting pituitary adenomas to a long-acting somatostatin analogue. N Engl J Med 317: 12-17.
6. Chanson P, Warnet A (1992) Treatment of thyroid-stimulating hormone-secreting adenomas with octreotide. Metabolism 41: 62-65.
7. Chanson P, Weintraub BD, Harris AG (1993) Octreotide therapy for thyroid-stimulating hormone-secreting pituitary adenomas. A follow-up of 52 patients. Ann Intern Med 119: 236-240.
8. Reichlin S (1983) Somatostatin. N Engl J Med 309: 1556-1563.
9. Shimon I, Taylor JE, Dong JZ, Bitonte RA, Kim S, Morgan B, Coy DH, Culler MD, Melmed S (1997) Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation. J Clin Invest 99: 789-798.
10. Miller GM, Alexander JM, Bikkal HA, Katznelson L, Zervas NT, Klibanski A (1995) Somatostatin receptor subtype gene expression in pituitary adenomas. J Clin Endocrinol Metab 80: 1386-1392.
11. Nielsen S, Mellemkjaer S, Rasmussen LM, Ledet T, Olsen N, Bojsen-Moller M, Astrup J, Weeke J, Jorgensen JO (2001) Expression of somatostatin receptors on human pituitary adenomas in vivo and ex vivo. J Endocrinol Invest 24: 430-437.
12. Murabe H, Shimatsu A, Ihara C, Mizuta H, Nakamura Y, Nagata I, Kikuchi H, Nakao K (1996) Expression of somatostatin receptor (SSTR) subtypes in pituitary adenomas: quantitative analysis of SSTR2 mRNA by reverse transcription- polymerase chain reaction. J Neuroendocrinol 8: 605-610.
13. Guillermet-Guibert J, Lahlou H, Cordelier P, Bousquet C, Pyronnet S, Susini C (2005) Physiology of somatostatin receptors. J Endocrinol Invest 28: 5-9.
14. Hofland LJ, Lamberts SW (2004) Somatostatin receptors in pituitary function, diagnosis and therapy. Front Horm Res 32: 235-252.
15. Hofland LJ, van der Hoek J, Feelders R, van der Lely AJ, de Herder W, Lamberts SW (2005) Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects. J Endocrinol Invest 28: 36-42.
16. Greenman Y, Melmed S (1994) Heterogeneous expression of two somatostatin receptor subtypes in pituitary tumors. J Clin Endocrinol Metab 78: 398-403.
17. Usui T, Izawa S, Sano T, Tagami T, Nagata D, Shimatsu A, Takahashi JA, Naruse M (2005) Clinical and molecular features of a TSH-secreting pituitary microadenoma. Pituitary 8: 127-134.
18. Panetta R, Patel YC (1995) Expression of mRNA for all five human somatostatin receptors (hSSTR1-5) in pituitary tumors. Life Sci 56: 333-342.
19. Caron P, Arlot S, Bauters C, Chanson P, Kuhn JM, Pugeat M, Marechaud R, Teutsch C, Vidal E, Sassano P (2001) Efficacy of the long-acting octreotide formulation (octreotide-LAR) in patients with thyrotropinsecreting pituitary adenomas. J Clin Endocrinol Metab 86: 2849-2853.
20. Socin HV, Chanson P, Delemer B, Tabarin A, Rohmer V, Mockel J, Stevenaert A, Beckers A (2003) The changing spectrum of TSH-secreting pituitary adenomas: diagnosis and management in 43 patients. Eur J Endocrinol 148: 433-442.
21. Lee EJ, Kim KR, Lim SK, Lee HC, Kim DI, Kim SH, Huh KB (1994) Reduction in size of a thyrotropin-secreting pituitary adenoma treated with octreotide acetate (somatostatin analog). Eur J Endocrinol 131: 109-112.
22. Warnet A, Lajeunie E, Gelbert F, Duet M, Chanson P, Cophignon J, Harris AG (1991) Shrinkage of a primary thyrotropin-secreting pituitary adenoma treated with the long-acting somatostatin analogue octreotide (SMS 201-995). Acta Endocrinol (Copenh) 124: 487-491.
23. Sy RA, Bernstein R, Chynn KY, Kourides IA (1992) Reduction in size of a thyrotropin- and gonadotropin-secreting pituitary adenoma treated with octreotide acetate (somatostatin analog). J Clin Endocrinol Metab 74: 690-694.
24. Erem C, Hacihasanoglu A, Sari A, Onder Ersoz H, Ukinc K, Fidan S (2004) A rare case and a rapid tumor response to therapy: dramatic reduction in tumor size during octreotide treatment in a patient with TSH-secreting pituitary macroadenoma. Endocrine 25: 141-145.
25. Teramoto A, Sanno N, Tahara S, Osamura YR (2004) Pathological study of thyrotropin-secreting pituitary adenoma: plurihormonality and medical treatment. Acta Neuropathol 108: 147-153.
26. Batista DL, Zhang X, Gejman R, Ansell PJ, Zhou Y, Johnson SA, Swearingen B, Hedley-Whyte ET, Stratakis CA, Klibanski A (2006) The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. J Clin Endocrinol Metab 91: 4482-4488.
27. Melmed S, Sternberg R, Cook D, Klibanski A, Chanson P, Bonert V, Vance ML, Rhew D, Kleinberg D, Barkan A (2005) A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab 90: 4405-4410.
28. Kleinberg DL (2005) Primary therapy for acromegaly with somatostatin analogs and a discussion of novel peptide analogs. Rev Endocr Metab Disord 6: 29-37.
29. Colao A, Pivonello R, Auriemma RS, Briganti F, Galdiero M, Tortora F, Caranci F, Cirillo S, Lombardi G (2006) Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients. J Clin Endocrinol Metab 91: 2112-2118.
30. Park C, Yang I, Woo J, Kim S, Kim J, Kim Y, Sohn S, Kim E, Lee M, Park H, Jung J, Park S (2004) Somatostatin (SRIF) receptor subtype 2 and 5 gene expression in growth hormone-secreting pituitary adenomas: the relationship with endogenous srif activity and response to octreotide. Endocr J 51: 227-236.
31. Jaquet P, Saveanu A, Gunz G, Fina F, Zamora AJ, Grino M, Culler MD, Moreau JP, Enjalbert A, Ouafik LH (2000) Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes. J Clin Endocrinol Metab 85: 781-792.
32. Yoshihara A, Isozaki O, Hizuka N, Nozoe Y, Harada C, Ono M, Kawamata T, Kubo O, Hori T, Takano K (2006) Expression of Type 5 somatostatin receptor in TSH-secreting pituitary adenomas: A possible marker for predicting long-term response to octreotide therapy. Endocrine J 54: 133-138.